ITCI Intra-Cellular Therapies Inc.

13.48
+0.46  (+4%)
Previous Close 13.02
Open 13.07
Price To Book 2.09
Market Cap 737710942
Shares 54,726,331
Volume 168,050
Short Ratio
Av. Daily Volume 394,671

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due 2Q 2019.
ITI-007 - Monotherapy (Study 401)
Bipolar depression
Phase 3 interim analysis December 18, 2018 noted trial to stop due to futility.
ITI-007-201
Agitation in patients with dementia
PDUFA date September 27, 2019.
Lumateperone
Schizophrenia
Phase 3 enrollment to be completed 2H 2018.
ITI-007 - Adjunctive Therapy
Bipolar depression
Phase 3 top-line data due 2Q 2019.
ITI-007 - Monotherapy (Study 404)
Bipolar depression
Phase 1/2 top-line presented October 22, 2018.
ITI-214
Parkinson's disease (PD)

Latest News

  1. Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  2. Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast
  3. Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies — What Drives Growth in Today's Competitive Landscape
  4. Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
  5. Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares
  6. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI
  7. Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference
  8. Is Intra-Cellular Therapies Inc (ITCI) A Good Stock To Buy?
  9. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intra-Cellular Therapies, Inc. (ITCI)
  10. Intra-Cellular Therapies stock down 22% after discontinuation of Phase 3 trial
  11. Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease
  12. How Should Investors React To Intra-Cellular Therapies, Inc.’s (NASDAQ:ITCI) CEO Pay?
  13. Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology
  14. Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia
  15. Edited Transcript of ITCI earnings conference call or presentation 7-Nov-18 1:30pm GMT
  16. Does Intra-Cellular Therapies Inc (NASDAQ:ITCI) Have A High Beta?
  17. Intra-Cellular: 3Q Earnings Snapshot